Intercept Pharmaceuticals... (ICPT)
NASDAQ: ICPT
· Real-Time Price · USD
19.00
0.04 (0.21%)
At close: Nov 07, 2023, 10:00 PM
Intercept Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 317.68M | 306.48M | 294.52M | 315.15M | 330.33M | 345.57M | 370.39M | 363.47M | 354.33M | 341.03M | 321.7M |
Cost of Revenue | 633K | 860K | 984K | 1.52M | 2.5M | 2.74M | 3.05M | 3.1M | 2.85M | 4.02M | 5.28M |
Gross Profit | 317.05M | 305.62M | 293.54M | 313.63M | 327.83M | 342.83M | 367.34M | 360.37M | 351.48M | 337M | 316.42M |
Operating Income | -62.28M | -67.8M | -74.05M | -52.69M | -54.65M | -50.72M | -36.6M | -55.67M | -75.41M | -124.35M | -177.14M |
Interest Income | 10.49M | 13.93M | 11.11M | 8.3M | 5.24M | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -58.01M | -159.34M | -173.83M | -159.24M | -177.97M | -77.52M | -68.29M | -91.43M | -107.29M | -170.13M | -222.32M |
Net Income | -58.61M | 117.69M | 116.02M | 128.31M | 112.42M | -64.72M | -68.29M | -91.43M | -107.29M | -170.13M | -222.32M |
Selling & General & Admin | 211.86M | 209.69M | 196.33M | 188.68M | 193.86M | 203.92M | 221.59M | 230.85M | 240.22M | 257.5M | 293.21M |
Research & Development | 161.21M | 163.73M | 171.25M | 177.63M | 188.62M | 189.63M | 182.59M | 185.27M | 185.5M | 189.31M | 185.56M |
Other Expenses | n/a | n/a | -289K | -628K | -726K | -554K | 470K | 809K | 1.61M | 2.23M | 2.17M |
Operating Expenses | 373.07M | 373.43M | 367.59M | 366.31M | 382.47M | 393.55M | 404.19M | 416.13M | 425.73M | 446.81M | 478.77M |
Interest Expense | 9.98M | 13.02M | 16.08M | 19.94M | 32.45M | 41.31M | 47.35M | 53.1M | 50.04M | 48.67M | 48.7M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -28.6M | -28.6M | -28.6M |
Cost & Expenses | 373.7M | 374.29M | 368.57M | 367.83M | 384.98M | 396.29M | 407.23M | 419.23M | 428.58M | 450.84M | 484.05M |
Income Tax Expense | 8.62M | -274.21M | -284.28M | -281.97M | -270.02M | 7.58M | 14.8M | 14.8M | 12.13M | 12.13M | 12.13M |
Shares Outstanding (Basic) | 41.79M | 41.73M | 41.67M | 41.32M | 34.24M | 29.75M | 29.7M | 29.47M | 31.74M | 33.18M | 33.14M |
Shares Outstanding (Diluted) | 41.79M | 41.73M | 41.67M | 41.48M | 34.29M | 29.75M | 29.7M | 29.54M | 31.74M | 33.18M | 33.14M |
EPS (Basic) | -1.41 | 3.73 | 3.62 | 3.75 | 3.01 | -2.17 | -2.25 | -2.89 | -3.24 | -5.14 | -6.73 |
EPS (Diluted) | -1.41 | 3.72 | 3.61 | 3.74 | 3.00 | -2.17 | -2.25 | -2.89 | -3.24 | -5.14 | -6.73 |
EBITDA | -41.68M | -54.48M | -65.88M | -47.05M | -53.27M | -51.49M | -35.63M | -52.37M | -70.05M | -105.17M | -157.15M |
EBIT | -165.83M | -268.48M | -279.93M | -261.46M | -150.35M | -41.03M | -25.76M | -43.15M | -63.83M | -128.03M | -180.19M |
Depreciation & Amortization | 10.93M | 13.33M | 8.17M | 5.64M | 1.89M | 208K | 2.14M | 2.98M | 3.39M | 3.29M | 3.22M |